[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368206-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368206-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluating-tumour-mutational-burden-as-a-key-biomarker-in-personalized-cancer-immunotherapy-a-pan-cancer-systematic-review","Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy - A Pan-Cancer Systematic Review","","Tumour mutational burden (TMB) functions as an emerging biomarker for forecasting the efficacy of immune checkpoint inhibitors (ICIs). Its predictive performance is established in lung cancer and melanoma, yet remains uncertain for breast and prostate cancers. This systematic review evaluates TMB’s predictive value across four major cancer types and examines drivers behind variability, using a PRISMA-guided literature synthesis. Results show consistent benefit with high TMB in lung cancer and melanoma, while breast and prostate findings are inconclusive.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-tumour-mutational-burden-as-a-key-biomarker-in-personalized-cancer-immunotherapy-a-pan-cancer-systematic-review/368206/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-tumour-mutational-burden-as-a-key-biomarker-in-personalized-cancer-immunotherapy-a-pan-cancer-systematic-review/368206.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does tumour mutational burden (TMB) indicate in cancer immunotherapy?","Question",{"text":63,"@type":64},"TMB measures genetic mutations in cancer cells and is used to predict how effective immune checkpoint inhibitors (ICIs) will be for a patient.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"For which cancers is high TMB consistently linked to better outcomes?",{"text":68,"@type":64},"High TMB is consistently associated with improved outcomes in lung cancer and melanoma.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are the findings for breast and prostate cancers considered inconclusive?",{"text":72,"@type":64},"Evidence for breast and prostate cancers is inconsistent, and differences in how TMB is measured limit comparability and reliability, suggesting the need for complementary biomarkers or refined criteria.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368206,1790443542,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Systematic Review  \nEvaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review  \nAnca Zgura 1,2, Stefania Chipuc 2,*, Nicolae Bacalbasa 3, Bogdan Haineala 4, Anghel Rodica 1,2 and Vâlcea Sebastian 3  \nReceived: 29 December 2024  \nRevised: 23 January 2025  \nAccepted: 27 January 2025  \nPublished: 1 February 2025  \nCitation: Zgura, A.; Chipuc, S.; Bacalbasa, N.; Haineala, B.; Rodica, A.; Sebastian, V. Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review. Cancers 2025, 17, 480. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17030480  \nCorrection Statement: This article has been republished with a minor change. The change does not affect the scientific content of the article and further details are available within the backmatter of the website version of this article.  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology,“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; [anca.zgura@umfcd.ro](anca.zgura@umfcd.ro) (A.Z.)  \n2 Prof. Dr. Alexandru Trestioreanu Institute of Oncology, 022328 Bucharest, Romania  \n3 Department of Surgery,“Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; [nicolae.bacalbasa@umfcd.ro](nicolae.bacalbasa@umfcd.ro) (N.B.); [sebastian.valcea@gmail.com](sebastian.valcea@gmail.com) (V.S.)  \n4 Department of Urology,“Fundeni” Clinical Institute,“Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; [bhaineala@gmail.com](bhaineala@gmail.com)  \n* Correspondence: [stefania.chipuc@stud.umfcd.ro](stefania.chipuc@stud.umfcd.ro)  \nSimple Summary: Cancer treatment using immune checkpoint inhibitors (ICIs) has shown great success, but not all patients respond equally. Tumour mutational burden (TMB) is a measure of genetic mutations in cancer cells and is used to predict whether ICIs will be effective. While TMB is a reliable predictor in lung cancer and melanoma, its usefulness in breast and prostate cancers remains uncertain. This study reviewed existing research to assess how well TMB pre-dicts treatment outcomes in these four cancer types. The results confirmed that high TMB is linked to better re-sponses in lung cancer and melanoma. However, findings for breast and prostate cancers were inconsistent, sug-gesting that other factors may influence treatment success. Differences in how TMB is measured also make com-parisons difficult. To improve cancer treatment, future research should focus on refining TMB assessment methods and identifying additional markers that can help personalize therapy.  \nAbstract: Background: Tumour mutational burden (TMB) is an emerging biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy. While its role is well established in lung cancer and melanoma, its predictive value for breast and prostate cancers remains unclear. Objective: This systematic review aimed to assess the predictive value of TMB for ICI therapy across four major cancer types—lung, melanoma, breast, and prostate—and to explore factors contributing to the variability in its effectiveness as abiomarker. Methods: A systematic search and a review of the literature were conducted in accordance with PRISMA guidelines. Studies examining the relationship between TMB levels and clinical outcomes following ICI therapy in the specified cancers were analyzed. The data were synthesized to evaluate TMB’s predictive value and identify gaps in the current research. Results: High","cbCaiapz7k9u95qy","https://ap.wps.com/l/cbCaiapz7k9u95qy","pdf",644434,16,"English","# Introduction\n# Simple Summary\n# Abstract\n# Keywords\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What does tumour mutational burden (TMB) indicate in cancer immunotherapy?\",\"answer\":\"TMB measures genetic mutations in cancer cells and is used to predict how effective immune checkpoint inhibitors (ICIs) will be for a patient.\"},{\"question\":\"For which cancers is high TMB consistently linked to better outcomes?\",\"answer\":\"High TMB is consistently associated with improved outcomes in lung cancer and melanoma.\"},{\"question\":\"Why are the findings for breast and prostate cancers considered inconclusive?\",\"answer\":\"Evidence for breast and prostate cancers is inconsistent, and differences in how TMB is measured limit comparability and reliability, suggesting the need for complementary biomarkers or refined criteria.\"}]","Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy - A Pan-Cancer Systematic Review | PDF",1790175636,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05dd839ac7ea9c803aceda36d2ad3108.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa74857e1ffa37ec2a3dd90f028b065d.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe8518f48df2aebc18969ad9031f1718.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1bc950288af9babab19b07fdd85ab8d.webp",980,1385]